Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis
| Autor: | Mehmet Emir Erol, Adnan Yalçınkaya, Özlem Erçen Diken, Adem İlkay Diken, Muhammet Onur Hanedan |
|---|---|
| Přispěvatelé: | Hitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü |
| Rok vydání: | 2017 |
| Předmět: |
Male
Time Factors Cost-Benefit Analysis 030204 cardiovascular system & hematology 0302 clinical medicine Rivaroxaban Risk Factors Ambulatory Care 030212 general & internal medicine Hospital Costs Cost–Benefit Analysis health care economics and organizations Venous Thrombosis Ratio value Health Care Costs General Medicine Middle Aged Vitamin K antagonist Venous thrombosis Models Economic Treatment Outcome Anesthesia Cost analysis Female Drug Monitoring Cardiology and Cardiovascular Medicine medicine.drug Adult medicine.drug_class Hemorrhage Drug Costs 03 medical and health sciences Cost Savings Thromboembolism medicine Humans International Normalized Ratio Blood Coagulation Aged Retrospective Studies business.industry Warfarin Anticoagulants Tinzaparin medicine.disease business Venous thromboembolism Factor Xa Inhibitors |
| Zdroj: | Phlebology: The Journal of Venous Disease. 33:53-59 |
| ISSN: | 1758-1125 0268-3555 |
| DOI: | 10.1177/0268355516688358 |
| Popis: | Background Standard treatment for deep venous thromboembolism involves parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated with limitations including the need for frequent coagulation monitoring. The direct oral anticoagulant rivaroxaban is similarly effective to standard therapy as a single-drug treatment for venous thromboembolism and does not require routine coagulation monitoring. The aim of this analysis was to project the long-term costs and outcomes for rivaroxaban compared to standard of care (tinzaparin/warfarin). Methods A total of 184 patients who were under anticoagulant therapy with warfarin or rivaroxaban for extended deep venous thromboembolism were retrospectively evaluated; 59 received rivaroxaban and 125 received warfarin therapy. Assessments were made on age, gender, place of residence, the duration of anticoagulation, mean international normalized ratio value, the effective rate of international normalized ratio (time in the therapeutic range), bleeding-related complication rate, duration of hospitalization due to complications, the number of annual outpatient department admission, cost for drug, cost for hospitalization, cost for outpatient department admission and international normalized ratio measurements. Results The annual outpatient cost is higher in warfarin group (147.09 ± 78 vs. 62.32 ± 19.79 USD p Conclusion This analysis suggests that rivaroxaban has lower costs than warfarin in terms of outpatient department admission and hospital costs due to complications; however, warfarin was more economic when all cost parameters were considered. Time in the therapeutic range was found as 56% for warfarin that should be taken into account while analyzing costs and benefits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|